Targeting histone deacetylases for heart failure

HDACs are unique and attractive therapeutic targets for heart failure because of their positions far downstream in pathological signaling cascades. Confirmation of the validity and viability of approaches aimed at HDACs awaits in vivo proof-of-concept testing with novel small molecule regulators of these enzymes.